CryoPort clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
CryoPort Inc
CYRX · NASDAQ · USD · Market cap $911M · 684 employees
Cryoport, Inc.
Not enough data to screen yetPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price19.05 USD at the 20 Nov 2026 close
- Our value readFair vs our fair value, as of 20 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.11)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $15.00 to $26.00, base estimate $20.00 (screen dated 2026-11-20).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.11, read 2026-11-20
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
CryoPort Inc holds its Markup at $19.05. Consolidating, no directional conviction, held for 5 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 5 days |
| Price at the screen | $19.05 |
| Valuation | N/A trailing · -27.11 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 1.96 |
Five Screens: CYRX's Results
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 30.16% | Below 33% | Pass |
| Interest-bearing cash | 21.01% | Below 33% | Pass |
| Receivables | 37.11% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadThe Read, in Plain English
CryoPort clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
CryoPort clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 30%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Fair to fair value, as of 20 Nov 2026: it trades at roughly a 5% discount to our $20.00 fair value, none competitive moat, 7.70% revenue growth.
USD, 2026-11-20 screen. A 4.8% under base.
Street: 9 covering, consensus Strong Buy. Average target +5%.
| Forward P/E | -27.1x |
| EPS, trailing | -0.81 |
| EPS, forward | -0.66 |
| Revenue growth | +7.7%slow but positive growth |
| Profit margin | -20.1%currently unprofitable |
| Return on equity | -6.5%not currently earning a positive return on equity |
| FCF yield | -1.61% |
| Debt to equity | 0.47minimal debt: a conservative balance sheet |
| Current ratio | 2.08comfortably covers its short-term bills |
| Beta | 1.96much more volatile than the market |
| Short interest, float | 0.06% |
| 52-week range | 7.61 - 18.73 |
| Moat | NONE |
| Market cap | $911M |
| Employees | 684 |
CYRX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markdown to markup since the last review. Since the last review it dropped out of the Titan Ethical 500; saw its composite score ease.
The framework has shifted from accumulation to markdown since the last review.
Earnings landed in this window. Ethical screening: not fully scored yet.
Written on its date, before the outcome; never pruned.
- Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year? Yahoo Finance · 1 Oct 2026
- Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Growth Assumptions Simply Wall St. · 24 Aug 2026
- Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Growth Assumptions Yahoo Finance · 24 Aug 2026
- Cryoport (CYRX) Q2 2026 Earnings Call Transcript Motley Fool · 14 Aug 2026
- Cryoport (CYRX) Q2 2026 Earnings Call Transcript Yahoo Finance · 14 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $16.98 | +18.8% | · | $1,188 | +18.8% |
| 2 months | $17.02 | +18.5% | · | $1,185 | +18.5% |
| 3 months | $16.71 | +20.7% | · | $1,207 | +20.7% |
| 6 months | $14.00 | +44.1% | · | $1,441 | +44.1% |
| 1 year | $8.39 | +140.4% | · | $2,404 | +140.4% |
| 2 years | $6.70 | +201.0% | · | $3,010 | +201.0% |
| 3 years | $13.62 | +48.1% | · | $1,481 | +48.1% |
| 5 years | $72.25 | -72.1% | · | $279 | -72.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CYRX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.